Protagenic Therapeutics

Protagenic Therapeutics FCF Yield

The Free Cash Flow Yield of Protagenic Therapeutics (PTIX) as of Nov 16, 2026 is -431.55 %. In the previous year, Free Cash Flow Yield was -439.49 % — a change of -1.81% (higher).

FCF Yield

-431.55 %

YoY

-1.81%

Last updated:

Free Cash Flow Yield of Protagenic Therapeutics is 2025 -431.55 % . Free Cash Flow Yield of Protagenic Therapeutics was 2024 -439.49 % . It decreases by -1.81% higher compared to the previous year.

The Protagenic Therapeutics FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-111.65 USD
Jan 1, 2019
-50.86 USD
Jan 1, 2020
-140.58 USD
Jan 1, 2021
-291.70 USD
Jan 1, 2022
-208.00 USD
Jan 1, 2023
-401.66 USD
Jan 1, 2024
-439.49 USD
Jan 1, 2025
-431.55 USD
The Protagenic Therapeutics FCF Yield history
YEARFCF YieldYoY
-431.55 %-1.81%
-439.49 %+9.42%
-401.66 %+93.10%
-208.00 %-28.69%
-291.70 %+107.49%
-140.58 %+176.39%
-50.86 %-54.44%
-111.65 %-22.38%
-143.85 %+21.03%
-118.86 %+200.88%
-39.50 %-52.09%
-82.45 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Protagenic Therapeutics Stock analysis

What does Protagenic Therapeutics do? Protagenic Therapeutics, Inc. develops therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound PT00114 is a synthetic TCAP-1 peptide designed to dampen overactive stress responses. The company also has a portfolio of earlier stage neuropeptides targeting the TCAP pathway in preclinical evaluation. PT00114 has shown pre-clinical efficacy in animal models of depression, anxiety, substance abuse, addiction, and PTSD, including the Saleens test for opioid withdrawal. The company focuses on developing treatments for conditions where current therapies are limited or ineffective. Protagenic's products are developed for pharmaceutical companies and research institutions seeking novel treatments for neuropsychiatric disorders. The target segments include patients suffering from depression, anxiety, PTSD, and substance abuse disorders. The company's lead compound PT00114 and its neuropeptide portfolio are positioned as potential treatments for these conditions, with the aim of addressing unmet medical needs in mental health care. Protagenic Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Protagenic Therapeutics stock

Free Cash Flow Yield of Protagenic Therapeutics is -431.55 % in 2025.

Free Cash Flow Yield of Protagenic Therapeutics changed from -439.49 % to -431.55 %, representing a -1.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Protagenic Therapeutics since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Protagenic Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Protagenic Therapeutics

All Key Metrics — Protagenic Therapeutics